Subrenal Capsule Assay for Chemotherapy in Ovarian Cancer
Author Information
Author(s): P. Venesmaa, O. Ylikorkala
Primary Institution: Helsinki University Central Hospital
Hypothesis
Can the subrenal capsule assay (SRCA) improve chemotherapy selection for patients with recurrent ovarian cancer?
Conclusion
The SRCA is of limited value in selecting second-line chemotherapy for recurrent ovarian cancer.
Supporting Evidence
- 22 of 23 SRCA tests were evaluable.
- 4 of 11 patients with SRCA-guided chemotherapy survived at least 3 years.
- 6 of 23 control patients survived at least 3 years.
Takeaway
Doctors tried a new test to help choose chemotherapy for women with recurring ovarian cancer, but it didn't really help them live longer.
Methodology
The study involved 46 patients with recurrent ovarian cancer, where 23 underwent the SRCA and 23 served as controls, with various chemotherapy combinations tested on tumor samples.
Potential Biases
Some effective drugs could not be used due to side effects, potentially skewing results.
Limitations
The SRCA could only guide chemotherapy in half of the patients, and many received the same treatments as before.
Participant Demographics
Patients aged 25 to 76, with various types of ovarian cancer, primarily serous cystadenocarcinoma.
Want to read the original?
Access the complete publication on the publisher's website